Qualitative parameters of the colonic flora in Patients with HNF1A-MODY are different from those observed in type 2 diabetes mellitus by Mrozińska, Sandra et al.
Research Article
Qualitative Parameters of the Colonic Flora in Patients with
HNF1A-MODY Are Different from Those Observed in Type 2
Diabetes Mellitus
Sandra Mrozinska,1,2 Piotr Radkowski,3 Tomasz Gosiewski,4 Magdalena Szopa,1,2
Malgorzata Bulanda,4 Agnieszka H. Ludwig-Galezowska,1,3 Iwona Morawska,1,2
Agnieszka Sroka-Oleksiak,4 Bartlomiej Matejko,1 Przemyslaw Kapusta,3
Dominika Salamon,4 Maciej T. Malecki,1,2 Pawel Wolkow,3 and Tomasz Klupa1,2
1Department of Metabolic Diseases, Jagiellonian University Medical College, 15 Kopernika Street, 31-501 Kraków, Poland
2University Hospital, 36 Kopernika Street, 31-501 Kraków, Poland
3Center for Medical Genomics OMICRON, Jagiellonian University Medical College, 7c Kopernika Street, 31-034 Kraków, Poland
4Department of Microbiology, Jagiellonian University Medical College, 18 Czysta Street, 31-121 Kraków, Poland
Correspondence should be addressed to Tomasz Klupa; tomasz.klupa@uj.edu.pl
Received 7 June 2016; Revised 22 August 2016; Accepted 30 August 2016
Academic Editor: Marcus Pezzolesi
Copyright © 2016 Sandra Mrozinska et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Background. Type 2 diabetes mellitus (T2DM) is determined by genetic and environmental factors. There have been many studies
on the relationship between the composition of the gastrointestinal bacterial flora, T2DM, and obesity. There are no data, however,
on the gut microbiome structure in monogenic forms of the disease including Maturity Onset Diabetes of the Young (MODY).
Methods.The aim of the investigationwas to compare the qualitative parameters of the colonic flora in patients withHNF1A-MODY
and T2DM and healthy individuals. 16S sequencing of bacterial DNA isolated from the collected fecal samples using the MiSeq
platform was performed. Results. There were significant between-group differences in the bacterial profile. At the phylum level, the
amount of Proteobacteria was higher (𝑝 = 0.0006) and the amount of Bacteroidetes was lower (𝑝 = 0.0005) in T2DM group in
comparison to the control group. In HNF1A-MODY group, the frequency of Bacteroidetes was lower than in the control group
(𝑝 = 0.0143). At the order level, Turicibacterales was more abundant in HNF1A-MODY group than in T2DM group. Conclusions.
It appears that there are differences in the gut microbiome composition between patients with HNF1A-MODY and type 2 diabetes.
Further investigation on this matter should be conducted.
1. Introduction
Diabetesmellitus is a chronic disease that has become amajor
health and economic problem nowadays. 387 million people
in the world suffer from diabetes and it is forecast that the
number will be 205 million more in 2035 [1]. The health
expenditure in the United States reached 612 billion Amer-
ican dollars in 2014 [1]. The state expenses incurred on the
disease include not only medications, hospital inpatient care,
and medical visits but also indirect costs like absenteeism,
reduced productivity, and inability to work [2]. Because of
that, more attention is paid to prophylaxis of obesity as well
as to optimization and individualization of diabetes treatment
[3].
Type 2 diabetesmellitus (T2DM) is determined by genetic
and environmental causes. The risk factors contributing to
the disease are, inter alia, age, body mass index, physical
inactivity, and sedentary lifestyle [4, 5]. As far as genetic
factors predisposing to T2DMare concerned, genetic variants
modifying the risk of development of the disease have been
identified; however, altogether, they explain only a small
proportion of the genetic backgroundof T2DM[6, 7]. Among
possible causes of “missing heritability” gene, environment
interactions are mentioned [8]. In recent years, there have
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been many studies on the relationship between the composi-
tion of the gastrointestinal bacterial flora, T2DM, and obesity
[9–11].These analyses indicate that the etiology of the various
forms of diabetes, especially those associatedwith obesity and
insulin resistance, such as T2DM, may be related to intestinal
microflora [9, 10]. On the other hand,monogenic forms of the
disease, like Maturity Onset Diabetes of the Young (MODY),
are determinedmostly by genetic factors, withminor effect of
the environment. HNF1A-MODY is one of themost common
forms of subtypes of MODY [12, 13]. It is caused by mutation
in HNF1A (Hepatic Nuclear Factor 1 Alpha) gene. HNF1A-
MODY is characterized by progressive hyperglycemia, with
the onset of diabetes in youth. If not treated properly, it can
lead to micro- and macrovascular complications [14]. Unlike
in T2DM, HNF1A-MODY patients are usually slim [15].
The differences in the gut microbiota between patients with
T2DM and HNF1A-MODY in relation to healthy individuals
could be a new argument for an influence of microbiota
as an environmental risk factor for some forms of diabetes.
The gut microbiota perform multiple functions, produce
vitamins, inhibit the growth of potential pathogenic bacteria,
and lower the cholesterol level in blood [16]. The bacterial
metabolite indole can modulate the secretion of glucagon-
like peptide-1 (GLP-1) by L-cells [17]. It is hypothesized that
remission of diabetes after bariatric surgery is connectedwith
neurohormonal signaling or changes in the ecosystem of
microbiota of the gastrointestinal tract [18, 19]. The intestinal
microbiota play a role in the circulation of bile acids [20]. It is
suggested that the increased levels of bile acids after bariatric
operation stimulate GLP-1 secretion and lead to improve-
ment in glucose metabolism [21]. The nuclear farnesoid X
receptor (FXR) is also the molecular target for metabolic
condition after bariatric surgery. The new approach is to
assess the bacterial flora through the use of the noncultivated
methods allowed for identifying bacteria that are difficult to
culture [22].These include targeted gene sequencing, genome
sequencing, and shotgun metagenomic sequencing [23].
The Aim. The aim of the investigation was to compare the
qualitative parameters of the colonic flora in patients with
HNF1A-MODY diabetes, matched controls, and patients
with T2DM in a single stool sample.
2. Materials and Methods
The study was designed in collaboration with the Depart-
ment of Metabolic Diseases, Jagiellonian University Medi-
cal College, Kraków, Poland; University Hospital, Kraków,
Poland; and Center for Medical Genomics OMICRON and
Department ofMicrobiology, JagiellonianUniversityMedical
College, Kraków, Poland. The research was performed in the
years of 2013–2015. The project has obtained the consent of
the Ethics Committee of the Jagiellonian University number
KBET/272/B/2013.
Participants were the patients of the Department of
Metabolic Diseases and volunteers, all of whom consented to
participate in the research. We collected stool samples from
ten patients with HNF1A-MODY and twenty-three patients
with T2DM. All participants declared not using antibiotics 4
weeks prior to stool sample delivery and they denied having
met the exclusion criteria (see the following list).
Exclusion Criteria
Patients who did not agree to participate in the study
and who withdrew during the investigation
Patients below 18 years of age and over 65 years of age
Patients taking antibiotics for up to 30 days before
giving the sample of stool
Patients using probiotics
Patients with confirmed infection of the gastrointesti-
nal tract
Patients with chronic inflammatory bowel disease of
unknown etiology
Patients with active cancer (especially of the gastroin-
testinal tract)
Patients with immunodeficiency
Patients with features of liver damage (with the
exception of nonalcoholic fatty liver transaminase
levels less than three times the upper limit of the
normal level)
In most patients, blinded continuous glucose monitoring
(CGM, iPro2, Medtronic) was implemented. In addition, we
utilized results of stool sample analysis of healthy individuals
done previously (project supported by the National Science
Centre in Poland, number DEC-2011/03/D/NZ5/00551). One
control group of healthy individuals was matched with
MODY patients with respect to age and BMI (body mass
index), and the second one was matched to T2DM patients
with respect to age.
The bacterial DNA was isolated using Genomic Mini
AX Stool Spin (A&A Biotechnology) modified to include
enzymatic treatment (lysozyme, lysostaphin, and lyticase)
and bead-beating step. Libraries were prepared according to
Illumina 16S Metagenomic Sequencing Library Preparation
protocol (https://support.illumina.com/downloads/16s met-
agenomic sequencing library preparation.html). In short,
universal external primers were used to amplify regions V3
and V4 of 16S rDNA. After the polymerase chain reaction
(PCR) clean-up, samples were indexed, cleaned, and pooled.
10 pM libraries with 10% PhiX Spike-In were sequenced on
Illumina MiSeq using V3 sequencing kit (300 bp paired end
reads). Sample quality was evaluated using FastQC tool.
PCR primers and sequencing adapters were trimmed using
cutadapt. Resulting short reads were joined on overlapping
regions using fastq-join tool from ea-utils package. Both
joined and forward unjoined reads were used for further
analysis. Reads with base quality lower than 20 were filtered
out. OTUs (operational taxonomic units) were picked using
open-reference protocol. In the first step, closed reference
OTU picking is done against Green Genes 13.08 reference
database. Subsequent reads that failed to hit the reference
database were filtered out and used to perform de novo
OTU picking. Reads were clustered using UCLUST. Taxon-
omy assignments were performed with PyNAST. Singletons
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OTUs were removed before further analyses. Relative OTU
abundance was calculated using QIIME (http://qiime.org/).
To estimate alpha diversity Chao 1, the observed OTUs
and Phylogenetic Distance metrics were calculated. Both
weighted and unweighted UniFrac distances were calculated
to analyze beta diversity. Results were transformed using
PCoA and visualized with Emperor. Frequency of OTU
across sample groups was compared using nonparametric
ANOVA (Kruskal-Wallis test) and Mann-Whitney 𝑈 test.
Post hoc tests using Statistica were performed if there were
significant differences between groups. To correlate clinical
parameters with relative OTU abundance, Spearman’s Rho
test was applied. 𝑝 values were estimated using 𝑍 Fisher
transform test. To compare the clinical parameters, the ade-
quate parametric (𝑡-test) and nonparametric (Mann-Whitney
𝑈 test, Kruskal-Wallis test) tests were used.
As diet is concerned at disease diagnosis, all MODY
and T2DM patients were educated to follow the diet recom-
mended in diabetes with 40–50% of calories coming from
carbohydrates, 20–30% from fat, and 20% from protein. The
current diet knowledge and adherence were verified with the
questionnaire.
3. Results
3.1. The Groups’ Characteristics. There were 23 T2DM pati-
ents (13 women and 10 men) and 10 HNF1A-MODY individ-
uals (5 women and 5 men) included in the study.Themedian
age in the T2DM group was 60 (56–62) years and in the
HNF1A-MODY group was 36.5 (30–56), 𝑝 = 0.0133. The
mean duration of diabetes in T2DM group was 4.46 ± 2.95
years versus 19.1 ± 13.37 years, 𝑝 < 0.0001. The median
HbA1c (glycosylated haemoglobin) level in T2DM group was
8.12% (7.11%–8.78%) versus 7.205% (5.4%–7.86%),𝑝 = 0.0479,
respectively.Thefirst control group,matched for age (𝑝 = 1.0)
and BMI (𝑝 = 0.26) with HNF1A-MODY group, consisted
of 16 healthy individuals (11 women and 5 men) with median
age of 39.5 (31.5–49.5) years andmedian BMI of 23.77 (22.85–
24.95) kg/m2. Themedian BMI in HNF1A-MODY group was
25.74 (24.22–29) kg/m2 and inT2DMgroupwas 30.25 (27.68–
33.25) kg/m2, 𝑝 = 0.0290. The T2DM group differed in age
(𝑝 = 0.0006) and BMI (𝑝 < 0.0001) in comparison to the first
control group (Figure 1). The second control group consisted
of 10 people (7 women and 3 men). The median BMI in the
second control group was 25.57 (24.32–27.38) kg/m2, and the
median age was 56 (53.5–58) years. There was no difference
in age between this control group and T2DM group (𝑝 =
0.3059), but the groups differ in BMI (𝑝 = 0.0012).
Based on the questionnaire data, we found no major
differences in the dietary profile between T2DM and MODY
patients. The questionnaire included four possible answers
regarding following the prescribed diet: always, most of the
time, rarely, or never. The majority (16 out of 23 patients with
T2DM and 8 out of 10 individuals with MODY) declared
following always or most of the time the diet recommended
in diabetes with respect to the proportion of calories coming
from carbohydrates, fat, and protein and with respect to food
quality. Unfortunately, we had no reliable data concerning
diet in control group.
The patients’ treatment included metformin, sulfony-
lurea, acarbose, and insulin (Supplementary Material avail-
able online at http://dx.doi.org/10.1155/2016/3876764).
3.2. 16S rRNA Sequencing. The analysis of the samples by
sequencing obtained an average of 180353.52 paired reads
per sample, with median 140780 and standard deviation
152430.2. The best sample contained 843416 read pairs, while
the worst contained 40878. After preprocessing (removing
adapters, PCR primers, filtration of low quality bases, pair
joining, and removal of chimeric reads), we received an
average of 115782.34 readings per sample, with median 87994
and standard deviation 104992.4. The best sample contained
579694 readings, while the worst contained 16371. OTU
picking resulted in 30736 OTUs. Statistical analysis included
639 OTUs, those with abundance of at least 0.01%. The
bacterial composition was analyzed at the phylum, class,
order, family, and genus level.
3.3.The Bacteria Profile. Thebacteria and archaea profiles for
the first control, HNF1A-MODY, and T2DM at the phylum
level were as follows: Euryarchaeota 0.12% versus 0.11%
versus 0.13%; Actinobacteria 9.53% versus 9.31% versus 11.70;
Bacteroidetes 6.39% versus 1.09% versus 1.30%; Firmicutes
77.02% versus 87.36% versus 80.09%; Proteobacteria 0.36%
versus 0.35% versus 2.82%; Synergistetes 0.00% versus 0.00%
versus 0.10%; Tenericutes 0.05%versus 0.005%versus 0.001%;
Verrucomicrobia 6.52% versus 1.78% versus 3.85% (Figure 2).
There were significant differences between T2DM and the
first control groups at the phylum level (Kruskal-Wallis test
with a False Discovery Rate (FDR) correction). In T2DM
group, in comparison to the first control group, the amount
of Proteobacteria was higher (𝑝 = 0.0006) and the amount
of Bacteroidetes was lower (𝑝 = 0.0005). In HNF1A-MODY
group, the frequency of Bacteroidetes was lower than in
the control group (𝑝 = 0.0143). There were no significant
differences between T2DM and HNF1A-MODY groups at
the phylum level. The Firmicutes/Bacteroidetes (F/B) ratio
was significantly higher in both T2DM and HNF1A-MODY
groups than in the first control group (Figure 3). The Firmi-
cutes/Bacteroidetes ratio was correlated positively with the
HbA1c level in HNF1A-MODY group; we did not observe
such phenomenon in T2DM.
There were significant differences at the class level: the
proportion of Flavobacteria and Bacteroidia was higher in
the first control group than in T2DM and HNF1A-MODY
groups. The amount of Gammaproteobacteria was higher in
T2DM group than in the first control group (𝑝 = 0.0002).
The amount of Erysipelotrichi was higher in HNF1A-MODY
group than in the first control group and T2DM group
(supplementary data).
There were significant differences at the order level:
Flavobacteriales and Bacteroidales were higher in the first
control group than in HNF1A-MODY and T2DM groups.
Actinomycetales was lower in the first control group than
in HNF1A-MODY and T2DM groups. Turicibacterales was
higher in the first control group than in T2DM group (𝑝 =
0.0073), and also Turicibacterales was higher in HNF1A-
MODY group than in T2DM group. Enterobacteriales was
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Figure 1: Comparison of age and BMI between groups. To reveal differences in age and BMI, the Kruskal-Wallis test was performed. Data
presented as median (first–third quartiles). BMI: body mass index; MODY: Maturity Onset Diabetes of the Young; T2DM: type 2 diabetes
mellitus. (a) Median age in the first control group was 39.5 (31.5–49.5) years, in HNF1A-MODY was 36.5 (30–56) years, and in T2DM was
60 (56–62) years. There was no difference in age (𝑝 = 1.0000) between HNF1A-MODY and the first control group. The T2DM group was
older than the first control group (𝑝 = 0.0006) and HNF1A-MODY group (𝑝 = 0.0133). (b) Median BMI in the first control group was 23.77
(22.85–24.95) kg/m2, in HNF1A-MODY was 25.74 (24.22–29 kg/m2), and in T2DM was 30.25 (27.68–33.25) kg/m2. There was no difference
with respect to BMI (𝑝 = 0.2600) between HNF1A-MODY and the first control group. The T2DM group was characterized by higher BMI
than control group (𝑝 = 0.0000) and HNF1A-MODY group (𝑝 = 0.0290). ∗ indicates that there was a significant difference between this
group and control group.
higher in T2DM group than in the first control group.
Erysipelotrichales was higher in HNF1A-MODY group than
in the first control group and in T2DMgroup (supplementary
data).
There were significant differences at the family level:
Flavobacteriaceae and Bacteroidaceae were higher and
Promicromonosporaceae and the other family of Actinomyc-
etales were lower in the first control group than in both
T2DM and HNF1A-MODY groups. Enterobacteriaceae was
higher and Porphyromonadaceae was lower in T2DM group
than in the first control group (𝑝 = 0.004). The frequency
of Clostridiaceae and Turicibacteraceae was lower in T2DM
group than in the first control group and HNF1A-MODY
group. The amount of Erysipelotrichaceae was higher in
HNF1A-MODY group than in the first control group and
T2DM group (supplementary data).
There were significant differences at the genus level:
Bacteroides and the unnamed genus of Flavobacteriaceae
were higher and Cellulosimicrobium and the other genus of
the other family of Actinomycetales were lower in the first
control group than inT2DMandHNF1A-MODYgroups.The
amount of Parabacteroides, unnamed genus of Clostridiaceae,
Turicibacter, Lachnospira, and Anaerostipes was higher, and
the unnamed genus of Enterobacteriaceae was lower in the
first control group than in T2DM group. The frequency of
the other genus of Clostridiaceae and SMB53 was lower in
T2DM group than in the first control group and HNF1A-
MODY group (supplementary data).
Comparing the microbiome between T2DM group and
the second control group (matched with respect to age)
revealed the differences in the followingOTUs: the frequency
of Proteobacteria (phyla level), Actinomycetales (order level),
the other family of Actinomycetales, Promicromonospo-
raceae (family level), the other genus of the other fam-
ily of Actinomycetales, Cellulosimicrobium, Bulleidia, and
Eubacterium (genus level) was higher and the frequency
of Clostridiaceae, Ruminococcaceae (family level), and the
unnamed and the other genus of Clostridiaceae and SMB53
(genus level) was lower in T2DM group than in the second
control group (supplementary data).
The observed OTUs alpha diversity (𝑝 = 0.027) but not
Chao 1 (𝑝 = 0.063) was significantly lower in T2DM than in
the control group; there was no difference in alpha diversity
between control and HNF1A-MODY, HNF1A, and T2DM
groups (Figure 4).
The beta diversity analysis revealed the differences in
communities structure between T2DM and the second con-
trol group.
3.4. Continuous Glucose Monitoring. We obtained data of
continuous glucose monitoring from 21 patients with T2DM
and9patientswithHNF1A-MODY.Themean glucose level in
T2DMgroupwas 167.33±35.34mg/dL, and themean glucose
level in HNF1A-MODY group was 143.11 ± 38.07mg/dL;
the groups did not differ in mean glucose level (𝑡-test, 𝑝 =
0.1037). The percentage of time with glucose level above
140mg/dL was higher in T2DM group (Mann-Whitney 𝑈
test, 𝑝 = 0.0235); the percentage of time with glucose level
within 70–140mg/dL was higher in HNF1A-MODY group
(Mann-Whitney 𝑈 test; 29% (14%–54%) versus 49% (32%–
81%), 𝑝 = 0.0352); the percentage of time with glucose
level below 70mg/dL was higher in HNF1A-MODY group
(Mann-Whitney 𝑈 test; 2% (0%–6%) versus 0% (0%-0%),
𝑝 = 0.0127).
4. Discussion
This study for the first time compares the bacterial flora
of patients with HNF1A-MODY with the bacterial flora
of individuals with T2DM and control group. Herein, we
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Figure 2: Comparison of frequencies of OTUs at the phylum level: (a) between groups (the first control group, HNF1A-MODY group, and
T2DM group) and (b) between samples.
have shown for the first time significant differences in the
bacteria profile of stool samples betweenHNF1A-MODY and
both control and T2DM groups. It is true that the diabetes
subpopulations differed at the baseline in age, duration of
diabetes in years, BMI, and HbA1c. It is also possible that
other confounders like diet [24] ormedications [25–27] could
influence the results. Some differences between the control
group and diabetes cohorts can result from medications
including antidiabetic drugs [26, 27]. It was demonstrated
that the F/B ratio depends on age [28]. In infants and elders, it
is significantly lower than in adults. It has also been presented
that the obese people have increased F/B ratio [28].
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Figure 3: Box plots presenting the Firmicutes/Bacteroidetes ratio
comparison between groups. The Firmicutes/Bacteroidetes (F/B)
ratio was significantly higher in both T2DM (𝑝 = 0.0005)
and HNF1A-MODY (𝑝 = 0.0113) groups than in the control
group.There was no difference between T2DM and HNF1A-MODY
groups. To show differences in F/B ratio, the Kruskal-Wallis test
was performed. ∗ indicates that there was a significant difference
between this group and control group.
T2DM and HNF1A-MODY groups in comparison with
control group share some between-group differences but the
study also revealed some type of diabetes-related differences.
Between diabetes groups in OTU taxa, we observed that
the frequency of Turicibacterales was significantly higher in
HNF1A-MODY group than in T2DM group and in the first
control group than inT2DMgroup.Therewere no differences
between the first control and HNF1A-MODY groups. In the
study results, the amount of Enterobacterialeswas statistically
higher in T2DM group than in the first control group. We
cannot forget that only HNF1A-MODY group was matched
with respect to age and BMI with the first control group.
The baseline differences between T2DM and HNF1A-MODY
group could be prone to and mask some differences in the
microbiome profile between diabetes groups. Nevertheless,
the study showed differences in the bacterial profile between
HNF1A-MODY and control groups.This can be an argument
for the thesis that also HNF1A-MODY is associated with
changes in colonic bacterial flora.
The differences in microbiome profiles between the first
control group andT2DMgroupwere not the same as between
the second control group and T2DM group.This could result
from the differences in age; only the second control groupwas
matched with respect to age with the T2DM group. Still, the
second control group was not matched with respect to BMI
with the T2DM group.
In recent studies, it has been revealed that the alpha
diversity (within samples diversity) is decreased in obese
individuals [29], but no significant differences were found in
alpha diversity between healthy people and diabetes patients
[30, 31]. In our study, we observed lowerOTUs alpha diversity
in T2DM group than in the control group, but the groups
differ in BMI. We did not observe differences in alpha diver-
sity between HNF1A-MODY and both control and T2DM
groups. Nevertheless, the alpha diversity in HNF1A-MODY
group was lower than in the control group and higher than in
the T2DM group, but the differences were not significant.
One could suggest that the colonic microbiome plays a
different role in the metabolic control in T2DM in compar-
ison to HNF1A-MODY. This finding could have significant
clinical implication. One could speculate that manipulation
in the structure of gutmicrobiota, in order to improve glucose
metabolism in patients with diabetes, could be more effective
in some types of diabetes (like T2DM) than in others and
should be individualized to the type or subtype of diabetes.
Some bacteria that belong to the Firmicutes phylum are
butyrate producers.They play a key role in human gut energy
supply by producing butyrate, the main source of energy
for the colonic epithelium. Furthermore, butyrate improves
insulin sensitivity [32] and is able to trigger the secretion of
GLP-1 from L-cells [33]. Tolhurst et al. demonstrated that
short fatty acids stimulate the secretion of GLP-1 in vitro
[34]. Also, some suggest that there is a relationship between
the short fatty acid as histone deacetylases inhibitors and the
role of epigenetics in the development of diabetes [35]. It
has to be emphasized that, in recent studies, it is reported
that the amount of butyrate producers such as Roseburia
species and Faecalibacterium prausnitzii is lower in patients
affected with T2DM [11, 36]. In our data, the frequency of
the genus Faecalibacterium was 0.5% in control, 0.2% in
HNF1A-MODY, and 0.5% in T2DMgroup but the differences
did not approach a level of significance (𝑝 > 0.05). The
genus Roseburia was abundant in 0.5% in control, in 1.1% in
HNF1A-MODY, and in 0.3% in T2DM (𝑝 > 0.05 for each
comparison).
In our study, the relative abundance of Akkermansia
tended to be higher in the first control group (6.5%) than in
HNF1A-MODY (1.8%) and T2DM (3.9%) groups. Nonethe-
less, statistical significance was not reached (𝑝 > 0.05). It has
been shown that in humans the percentage of Akkermansia
muciniphila in the healthy population is 1–4% [37, 38]. The
abundance of the bacteria was reported to be decreased in
genetically (T2DM) and diet-induced obesity mice model
[39]. On the other hand, it has been shown that in T2DM
microbiota genes belonging to Akkermansia are increased
[36]. Of note, four individuals in the T2DM group had very
high relative abundance of Akkermansia: 31.4%, 32.1%, 21.1%,
and 20.6%.Three controls from the first control group (29.2%,
17.8%, and 14.3%) and two HNF1A-MODY patients (9.5%
and 13.7%) were also characterized by high frequency of
Akkermansia. It was demonstrated that higher amount of
Akkermansia muciniphila in overweight and obese people
resulted in healthier metabolic status and better glucose
homeostasis after introducing calorie restriction diet [40].
Definitely, one of the limitations of our study is due to the
age differences between the T2DM and MODY individuals.
The difference is due to the fact that MODY individuals are
usually diagnosed at much younger age in comparison to
patients with type 2 diabetes. The individuals from older
generations representing MODY families were usually not
available for genetic testing (either death or no willingness
for testing). On the other hand, hardly ever do we diagnose
type 2 diabetes in patients below 50 years of age. This is why
matching T2DM and MODY patients for the age was not
possible. To address these differences, we used two separate
control groups. The first one was matched with MODY
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Figure 4: Box plots showing the alpha diversity ((a) observed OTUs, (b) Chao 1) comparison between groups. The rarefaction plots
comparison ((c) observed OTUs, (d) Chao 1). Bold line: median; black lines: range of values. The observed OTUs but not Chao 1 alpha
diversity were lower in T2DM group than in the control group. There were no significant differences in alpha diversity between T2DM and
MODYandMODYand control groups. (a)ObservedOTUalpha diversity: control versusMODY,𝑝 = 0.846; control versus T2DM,𝑝 = 0.027;
MODY versus T2DM, 𝑝 = 0.726. (b) Chao 1 alpha diversity: control versus MODY, 𝑝 = 1; control versus T2DM, 𝑝 = 0.063; MODY versus
T2DM, 𝑝 = 0.816. OTU: operational taxonomic unit; T2DM: type 2 diabetes mellitus; MODY: Maturity Onset Diabetes of the Young. ∗
indicates that there was a significant difference between this group and control group.
individuals with respect to age and BMI. The second one
was matched with T2DM patients with respect to age. We
failed, however, to match controls with T2DM as far as BMI
is concerned (nondiabetic obese individuals were not willing
to follow the study protocol).
Another limitation was related to the way we assessed
dietary profiles of our patients. The estimation was based on
a self-reported questionnaire and was not verified; thus, we
cannot fully exclude the notion that the results of our study to
some degree were affected by differences in dietary patterns.
However, the major limitation of our study was the
relatively small sample size, which was partially due to
protocol requirements. Follow-up studies based on larger
groups are required to confirm the findings.
Comparison of bacterial profiles between patients with
HNF1A-MODY and individuals with mutation in HNF1A
gene without clinical diabetes could be significant.
It could be suggested that all of the particular genus
of bacteria, proportion of bacteria (including shifts and the
proportionwithin the same phyla, class, order, or family), and
percentage of bacteriawith the same function should be taken
into account in consideration of the influence of microbiota
on the development of different types of diabetes.
The differences in microbiota between patients with
different types of diabetes could be also a novel strategy in
distinguishing subtypes of diabetes.
In conclusion, it appears that there are differences in
gut microbiome composition between patients with HNF1A-
MODY, control individuals, and patients with type 2 dia-
betes. The clinical importance of this finding remains to be
explored.
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